Clarius Group LLC Decreases Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Clarius Group LLC trimmed its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 9.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 10,000 shares of the biopharmaceutical company’s stock after selling 994 shares during the quarter. Clarius Group LLC’s holdings in Sage Therapeutics were worth $217,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its stake in shares of Sage Therapeutics by 3,361.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 19,040 shares of the biopharmaceutical company’s stock valued at $413,000 after purchasing an additional 18,490 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Sage Therapeutics by 353.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 5,406 shares during the period. Values First Advisors Inc. raised its stake in shares of Sage Therapeutics by 59.8% in the fourth quarter. Values First Advisors Inc. now owns 16,980 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 6,354 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Sage Therapeutics in the 4th quarter worth approximately $293,000. Finally, Vanguard Group Inc. lifted its stake in Sage Therapeutics by 3.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,208,002 shares of the biopharmaceutical company’s stock valued at $107,181,000 after acquiring an additional 175,565 shares during the period. Institutional investors own 99.22% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SAGE. JPMorgan Chase & Co. raised their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, March 26th. Stifel Nicolaus decreased their price objective on Sage Therapeutics from $22.00 to $20.00 and set a “hold” rating for the company in a report on Monday, December 18th. Royal Bank of Canada raised their target price on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. HC Wainwright boosted their price target on Sage Therapeutics from $25.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Finally, StockNews.com raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, February 15th. Fifteen equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $41.00.

Sage Therapeutics Stock Down 0.8 %

Shares of SAGE opened at $15.32 on Tuesday. Sage Therapeutics, Inc. has a 52-week low of $15.06 and a 52-week high of $59.99. The stock has a fifty day simple moving average of $20.47 and a two-hundred day simple moving average of $21.05.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics’s revenue was up 2621.5% on a year-over-year basis. During the same period in the previous year, the business posted ($2.47) EPS. As a group, research analysts predict that Sage Therapeutics, Inc. will post -6.05 EPS for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.